This comprehensive report from VPGMarketResearch.com contains 350 pages, 22 tables, and is designed to help current suppliers and potential market entrants identify and evaluate emerging business opportunities during the next five years.
The report explores market and technological trends; provides reagent, instrument and test volume for 40 coagulation procedures; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.
Coagulation Tests Analyzed in the Report
Activated Clotting Time (ACT) (1), Activated Protein C Resistance, Activated PTT (APTT), Alpha 2-Antiplasmin, Antithrombin III, Bleeding Time, D-Dimer, Factor II, Factor V, Factor V Leiden, Factor VII, Factor VIII, Factor IX, Factor Ixa, Factor X (Stuart Factor), Factor Xa, Factor XI, Factor XII, Factor XIII, Fibrin Degradation Products, Fibrinogen, Fletcher Factor/Pre-Kallikrein Factor Activation, Heparin/Anti-Factor Xa, Heparin-Induced Thrombocytopenia, Plasmin, Plasminogen, Plasminogen Activator Inhib., Platelet Function/Aggregation, Protein C, Protein S, Prothrombin Mutation, Prothrombin Time (PT), Reptilase Time, Thrombin Time, Von Willebrand's Factor Fav/Ag, and others.
- Extensive strategic profiles of major suppliers and emerging market entrants.
Current and Emerging Products
- Review of established and emerging procedures.
- Comparison of automated and semi-automated analyzers.
- Analysis of current and emerging technologies and their potential market applications.
- Comprehensive listings of companies developing or marketing new technologies and products by test.
- Product development and business expansion opportunities with significant market appeal.
- Alternative market penetration strategies for instrument and reagent suppliers.
- Potential market entry barriers and risks.
Contains 350 pages and 22 tables
SIMILAR MARKET STUDIES
November 2013 | $6300 | View Details >>
Targeting unmet needs in the treatment of cancer/ hematological malignancies through innovative drug development strategies have witnessed favorable outcomes. Over the past decade, Proteasome inhibitor, Velcade (bortezomib) and the immunomodulatory drugs - Thalomid (thalidomide) and Revlimid (lenalidomide) have become the cornerstone of treatment for patients with Multiple Myeloma (MM) resulting ...
February 2014 | $2500 | View Details >>
This DataPack presents French test volume and sale forecasts for HIV-1/2/Combo, HIVAg, NAT, Western Blot, and other confirmatory assays performed in the following market segments: - Hospitals - Commercial/Private Labs - Blood BanksThe DataPack also provides sales and market share estimates for major suppliers of AIDS tests, including Abbott, ...
June 2016 | $0 | View Details >>
2016-2020 World HIV/AIDS Diagnostic Testing Market: Blood Banks, Commercial Labs, Hospitals, Physician Offices, Public Health Labs--Supplier Shares, Competitive Strategies, Country Volume and Sales Segment Forecasts
The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses are reviewed. The report provides the 5- and 10-year test volume and sales ...
March 2016 | $0 | View Details >>
UPCOMING MARKET RESEARCH REPORTS
2017 © Copyright Big Market Research